(WASHINGTON) – The American Society of Hematology (ASH), the world’s
largest professional society concerned with the causes and treatment of blood
disorders, today announced the election of three new members to its Executive
Committee, the governing body of the organization, for terms beginning after
the 2013 ASH Annual Meeting.
Charles S. Abrams,
MD, will serve a one-year term as vice president, followed by successive terms
as president-elect and president. Michelle Le Beau, PhD, and Martin Tallman, MD,
will both serve four-year terms as councillor.
Charles S. Abrams, MD
Michelle Le Beau, PhD
Martin S. Tallman, MD
“This is an exciting
yet challenging time for the field,” said 2013 ASH President Janis L. Abkowitz,
MD, of the University of Washington. “While we are poised to make great
discoveries, we are also faced with the continual threat of decreased federal research
funding and significant changes in the health-care system that allows us to
deliver care to our patients. Navigating these opportunities and challenges
requires strong, visionary leaders like Drs. Abrams, Le Beau, and Tallman.”
Charles S. Abrams,
MD, is Director of the University of Pennsylvania School of Medicine and
Children’s Hospital of Philadelphia Blood Center for Patient Care &
Discovery and Associate Chief of Hematology/Oncology at the University of
Pennsylvania. His major fields of interest include phosphoinositide signaling in hematopoietic cells, platelet
adhesion and thrombosis and murine models of hemostasis. Outside of the
laboratory, Dr. Abrams is interested in mentoring young hematologists and developing
continuing medical education programs in clinical hematology. Dr. Abrams previously served a four-year
term as ASH Secretary from 2009 to 2012.
Beau, PhD, is Director of University of Chicago Comprehensive Cancer Center and
the University of Chicago Cancer Cytogenetics Laboratory and the Arthur and
Marian Edelstein Professor of Hematology/Oncology at the University of Chicago.
Her major research interests include cancer cytogenetics and genetics, genetic
pathways that lead to myelodysplastic syndromes, acute myeloid leukemia, and
therapy-related myeloid neoplasms.
Tallman, MD, is Chief of the Leukemia Service at Memorial Sloan-Kettering
Cancer Center and Professor of Medicine at Weill Cornell Medical College in New
York. He also served as Chair of the Leukemia Committee of the Eastern
Cooperative Oncology Group for 16 years. Dr. Tallman’s fields of interest
include clinical investigation in acute myeloid and acute lymphocytic leukemia,
acute promyelocytic leukemia, and hairy cell leukemia.
who wish to arrange an interview with a newly elected Executive Committee
member may contact Kaitlin Bressler, ASH Communications Associate, at
202-552-4925 or email@example.com.
Society of Hematology is the world’s largest professional society concerned with the causes and
treatment of blood disorders. Its mission is to further the understanding,
diagnosis, treatment, and prevention of disorders affecting blood, bone marrow,
and the immunologic, hemostatic, and vascular systems by promoting research,
clinical care, education, training, and advocacy in hematology. The official
journal of ASH is Blood,
the most cited peer-reviewed publication in the field, which is available
weekly in print and online.
back to top